iBio

IBIOPhase 1

iBio is focused on creating transformative antibody therapies for obesity and cardiometabolic disorders by integrating artificial intelligence with experimental biology. Its platform enables the discovery of antibodies against challenging targets like GPCRs, with a pipeline featuring candidates designed to preserve muscle mass, target fat selectively, and enable less frequent dosing. The company is advancing multiple programs from discovery through IND-enabling stages, positioning itself in the rapidly expanding obesity therapeutics market.

Focus

AntibodiesBiologics

IBIO · Stock Price

USD 2500.005950.00 (-70.41%)

Historical price data

AI Company Overview

Technology Platform

An AI-integrated drug discovery platform combining Epitope-Steering technology, Mammalian Display, and StableHu™ AI-optimized libraries to design and select fully human, developable antibodies against hard-to-drug targets like GPCRs.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
PHI-101 administration	Platinum-resistant Ovarian Cancer	Phase 1
IBIO-600 + Placebo	Overweight , Obesity	Phase 1
PHI-101	Relapsed or Refractory Acute Myeloid Leukemia	Phase 1

Opportunities

The massive, growing obesity market creates a multi-billion dollar opportunity for next-generation therapies that address the limitations of current GLP-1s, particularly muscle preservation.

iBio's antibody platform also has potential for expansion into other therapeutic areas like immunology and infectious diseases through partnerships.

Risk Factors

High clinical development risk as all programs are pre-clinical.

Intense competition from large pharma and well-funded biotechs.

Financial dependency on capital markets as a pre-revenue company.

Need to clinically validate the AI platform's output.

Competitive Landscape

Competes against dominant GLP-1 makers (Novo Nordisk, Eli Lilly) and numerous biotechs developing next-gen peptides and small molecules. iBio differentiates through an antibody-based approach offering potential for less frequent dosing and high specificity, enabled by its AI platform targeting difficult mechanisms like GPCR modulation.